BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15549184)

  • 1. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?
    Dunst J
    Strahlenther Onkol; 2004 Nov; 180(11):671-81. PubMed ID: 15549184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anemia impact on treatments of cervical carcinomas].
    Marchal C; Rangeard L; Brunaud C
    Cancer Radiother; 2005 Mar; 9(2):87-95. PubMed ID: 15820436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
    Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
    Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia, tumor hypoxemia, and the cancer patient.
    Varlotto J; Stevenson MA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):25-36. PubMed ID: 16111569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
    Durmaz O; Demirkaya M; Sevinir B
    Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy.
    Dunst J
    Semin Oncol; 2001 Apr; 28(2 Suppl 8):42-8. PubMed ID: 11395852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
    Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
    Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of darbepoetin alfa in relation to cancer patients' hemoglobin levels.
    Hess G; Hill J; Clough J; Hulnick S; Nordyke RJ
    Curr Med Res Opin; 2008 Mar; 24(3):815-9. PubMed ID: 18257979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
    Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
    Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hemoglobin levels on tumor oxygenation: the higher, the better?
    Vaupel P; Mayer A; Höckel M
    Strahlenther Onkol; 2006 Feb; 182(2):63-71. PubMed ID: 16447012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-related anemia and recombinant human erythropoietin--an updated overview.
    Bohlius J; Weingart O; Trelle S; Engert A
    Nat Clin Pract Oncol; 2006 Mar; 3(3):152-64. PubMed ID: 16520805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy.
    Serkies K; Badzio A; Jassem J
    Acta Oncol; 2006; 45(6):695-701. PubMed ID: 16938812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Erythropoietin: a study of its use in oncohematology].
    Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
    Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.
    Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P
    Eur J Cancer; 2004 Oct; 40(15):2201-16. PubMed ID: 15454245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.